Table 3.
Baseline characteristics of patients who developed and did not develop adverse events.
| Variable | Patients who did not develop adverse events, n = 53 | Patients who developed adverse events, n = 4 |
|---|---|---|
| Age [yrs] | 52.8 | 53.2 |
| Sex [F:M] | 6:47 | 1:3 |
| Smoking, n [%] | 24 [45] | 0 [0] |
| Diabetes, n [%] | 15 [28] | 2 [50] |
| Hypertension, n [%] | 19 [36] | 0 [0] |
| Obesity, n [%] | 15 [28] | 1 [25] |
| Dyslipidemia, n [%] | ||
| Hypercholesterolemia | 15 [28] | 3 [75] |
| High LDL | 44 [83] | 3 [75] |
| Low HDL | 40 [75] | 3 [75] |
| Tirofiban use, n [%] | 23 [43] | 2 [50] |
| Type of stent | ||
| Bare metal stent, n [%] | 35 [66] | 2 [50] |
| Drug eluting stent, n [%] | 18 [34] | 2 [50] |
| Fibrinogen level [mg/dL] | 288.64 ± 59.43* | 393.75 ± 32.97* |
*p = 0.003.